VGX International, Inc. to terminate that certain CELLECTRA Device License Agreement, dated April 16, 2008, by and between the VGX Pharmaceuticals, Inc. and GeneOne. Under the CELLECTRA Agreement, VGXP granted GeneOne exclusive rights to the development, sales, licensing and marketing of the company’s CELLECTRA device, which uses electroportation technology for the delivery of DNA medicines into skeletal muscle cells and skin, for human use in the Republic of Korea. The CELLECTRA Agreement permits VGXP to terminate the agreement upon the occurrence of specified events related to the ownership of GeneOne, with 60 days’ prior written notice to GeneOne. Accordingly, the termination of the CELLECTRA Agreement will be effective as of December 8, 2020.